You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)合作伙伴施維雅公司公佈艾伏尼布聯合阿扎胞苷的III期研究結果顯示可顯著改善初治IDH1突變急性髓系白血病患者的無事件生存期和總生存期
格隆匯 12-12 18:38

格隆匯12月12日丨基石藥業-B(02616.HK)發佈公吿,基石藥業合作伙伴施維雅於2021年12月12日公佈了全球AGILE研究的III期臨牀試驗數據。研究結果顯示,與安慰劑聯合化療藥物阿扎胞苷相比,艾伏尼布?(ivosidenib片劑)聯合阿扎胞苷顯著提高了初治易感異檸檬酸脱氫酶-1(“IDH1”)突變急性髓系白血病(“AML”)患者的無事件生存期(“EFS”)和總生存期(“OS”)。這些數據將於美國東部時間2021年12月13日(週一)下午2:45-4:15在第63屆美國血液學會年會暨博覽會以口頭報吿形式公佈(摘要編號:697),並被納入大會的官方新聞發佈中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account